Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Artificial neural network for optimizing the formulation of curcumin-loaded liposomes from statistically designed experiments

Curcumin is a primary polyphenol of the rhizomatous perennial plant called Curcuma Longa. Curcumin interferes favorably with the cellular events that take place in the inflammatory and proliferative stages of wound healing, hence its importance in skin regeneration and wound healing. Curcumin is however lipophilic, and this must be considered in the choice of its drug delivery system. Liposomes are spherical vesicles with bi-lipid layers. Liposomes can encapsulate both lipophilic and hydrophilic drugs, hence their suitability as an ideal drug delivery system for curcumin. There is, nevertheless, a tendency for liposomes to be unstable and have low encapsulation efficiency if it is not formulated properly. Formulation optimization of curcumin-loaded liposomes was studied by the application of artificial neural network (ANN) to improve encapsulation efficiency and flux of the liposomes. The input factors selected for optimization of the formulation were sonication time, hydration volume, and lipid/curcumin ratio. The response variables were encapsulation efficiency and flux. The maximum encapsulation efficiency and flux were obtained using lipid/curcumin ratio of 4.35, sonicator time of 15 min, and hydration volume of 25 mL. The maximum encapsulation efficiency and flux predicted were 100% and 51.23 µg/cm²/h, respectively. The experimental values were 99.934% and 51.229 µg/cm²/h, respectively. Curcumin-loaded liposome formulation is a promising drug delivery system in the pharmaceutical industry when formulated using optimized parameters derived from ANN statistically designed models.

Recent approaches and success of liposome-based nanodrug carriers for the treatment of brain tumor

Brain tumors are nothing but a collection of neoplasms originated either from areas within the brain or from systemic metastasized tumors of other organs that have spread to the brain. It is a leading cause of death worldwide. The presence of the blood-brain barrier (BBB), blood-brain tumor barrier (BBTB), and some other factors may limit the entry of many potential therapeutics into the brain tissues in tumor area at the therapeutic concentration required for satisfying effectiveness. Liposomes are taking an active role in delivering many drugs through the BBB into the tumor due to their nanosize and their physiological compatibility. Further, this colloidal carrier can encapsulate both lipophilic and hydrophilic drugs due to its unique structure. The surface of the liposomes can be modified with various ligands that are very specific to the numerous receptors overexpressed onto the BBB as well as onto the diseased tumor surface site (i.e., BBTB) to deliver selective drugs into the tumor site. Moreover, the enhanced permeability and retention (EPR) effect can be an added advantage for nanosize liposomes to concentrate into the tumor microenvironment through relatively leaky vasculature of solid tumor in the brain where no restriction of penetration applies compared to normal BBB. Here in this review, we have tried to compilethe recent advancement along with the associated challenges of liposomes containing different anticancer chemotherapeutics across the BBB/BBTB for the treatment of gliomas that will be very helpful for the readers for better understanding of different trends of brain tumor targeted liposomes-based drug delivery and for pursuing fruitful research on the similar research domain.

Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases

Polyphenols play a therapeutic role in vascular diseases, acting in inherent illness-associate conditions such as inflammation, diabetes, dyslipidemia, hypertension, and oxidative stress, as demonstrated by clinical trials and epidemiological surveys. The main polyphenol cardioprotective mechanisms rely on increased nitric oxide, decreased asymmetric dimethylarginine levels, upregulation of genes encoding antioxidant enzymes via the Nrf2-ARE pathway and anti-inflammatory action through the redox-sensitive transcription factor NF-κB and PPAR-γ receptor. However, poor polyphenol bioavailability and extensive metabolization restrict their applicability. Polyphenols carried by nanoparticles circumvent these limitations providing controlled release and better solubility, chemical protection, and target achievement. Nano-encapsulate polyphenols loaded in food grade polymers and lipids appear to be safe, gaining resistance in the enteric route for intestinal absorption, in which the mucoadhesiveness ensures their increased uptake, achieving high systemic levels in non-metabolized forms. Nano-capsules confer a gradual release to these compounds, as well as longer half-lives and cell and whole organism permanence, reinforcing their effectiveness, as demonstrated in pre-clinical trials, enabling their application as an adjuvant therapy against cardiovascular diseases. Polyphenol entrapment in nanoparticles should be encouraged in nutraceutical manufacturing for the fortification of foods and beverages. This study discusses pre-clinical trials evaluating how nano-encapsulate polyphenols following oral administration can aid in cardiovascular performance.

Addressing Antimicrobial Resistance Through Nanoantibiotics

In recent years, the irrational use of antibiotics has escalated the evolution of multidrug-resistant (MDR) bacterial strains. The infectious diseases caused by these MDR bacterial strains remain a major threat to human health and have emerged as the leading cause of morbidity and mortality. The WHO and CDC have expressed serious concern regarding the continued increase in the development of multidrug resistance among bacteria. The antimicrobial resistance (AMR) poses a severe global threat of growing concern to human health and economic burden. Bacteria have developed the ability to resist antimicrobials by altering target site/enzyme, inactivation of the enzyme, decreasing cell permeability, increasing efflux due to over-expression of efflux pumps, target protection, target overproduction, and many other ways. The shortage of new antimicrobials and rapid rise in antibiotic resistance demands pressing need to develop alternate antibacterial agents.